Targeting a specific protein in certain types of uterine cancer
Official title: Targeting WEE1 in uterine serous or p53-mutated uterine cancer
Funded at Dana-Farber Cancer Inst · NIH-11070304 · Data updated 2026-11-12
This study is looking at a type of uterine cancer that can be hard to treat, and it’s testing a new approach that targets a specific protein to see if it can help improve treatment options for patients like you.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $494,028 |
| NIH project number | 5P01CA269021-02 |
| Project ID | NIH-11070304 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with uterine serous carcinoma or p53-mutated uterine cancer.
✕Less likely to help
Patients with other types of uterine cancer or those who do not have p53 mutations may not benefit from this research.
What this research studies
This research focuses on uterine serous carcinomas and p53-mutated uterine cancers, which are known for their poor prognosis and limited treatment options. The study aims to explore the effectiveness of inhibiting the WEE1 protein, which may help these cancers that often exhibit cell cycle dysregulation and high replication stress. By analyzing the response to WEE1-targeting agents, the research seeks to identify potential new therapies that could improve patient outcomes. Patients may be involved in clinical trials assessing the safety and efficacy of these targeted treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with aggressive forms of uterine cancer.
How similar studies have gone: Previous clinical trials targeting WEE1 in similar cancers have shown promising results, indicating potential for success in this approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Liu, Joyce — Dana-Farber Cancer Inst
- Study coordinator: Liu, Joyce
Related research
Other NIH-funded projects on the same topics.
-
Modeling to Prevent and Control Uterine Cancer
A national modeling effort uses computer simulations to inform better prevention, screening, and treatment of uterine cancer for women.
-
Comparative modeling to guide uterine cancer care
This grant uses computer models to help doctors and patients understand how to make better decisions about uterine cancer care.
-
Using DNA damage drugs to help the immune system fight uterine cancer
This project combines drugs that increase tumor DNA damage with immunotherapy to help people with recurrent microsatellite-stable uterine cancer who haven't responded to current treatments.
-
Dual ATR and PI3K-targeted therapy for uterine cancer
This project will try combining two drugs that block ATR and PI3K to better stop uterine cancers, especially tumors with ARID1A changes or other DNA replication stress.
-
WEE1-targeted treatment for uterine serous and p53-mutant uterine cancer
Testing a drug that blocks the WEE1 protein to try to shrink uterine serous cancers and other uterine cancers with p53 mutations.
-
Treating uterine (endometrial) cancer by targeting DNA damage and replication stress
This project develops new treatment approaches that exploit DNA repair weaknesses to help women with advanced or recurrent uterine (endometrial) cancer who need additional options.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.